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Abstract 
INTRODUCTION: Type 1 Diabetes Mellitus (T1D) is an autoimmune disease that results from the destruction of 
insulin-producing beta cells of the pancreas by autoreactive T cells. Myeloid-derived suppressor cells (MDSCs) 
are a heterogeneous population of cells that can potently suppress T cell responses. 
AIM: To detect the presence of MDSCs in T1D and compare their percentage in T1D versus healthy individuals.  
METHOD: Thirty T1D patients were included in the study. Diabetic patients with nephropathy (n = 18) and 
diabetic patients without nephropathy (n = 12). A control group of healthy individuals (n = 30) were also included. 
CD33
+
 and HLA-DR
–
 markers were used to identify MDSCs by flow cytometry. CD14 positive and negative 
MDSCs subsets were also identified. 
RESULTS: MDSCs was significantly increased in T1D than the control group and diabetic patient with 
nephropathy compared to diabetic patients without nephropathy. M-MDSCs (CD14
+
 CD33
+
 HLA–DR
−
) were the 
most abundant MDSCs subpopulation in all groups, however their percentage decrease in T1D than the control 
group. 
CONCLUSION: MDSCs are increased in the peripheral blood of T1D with a predominance of the CD14
+
 MDSCs 
subset. Future studies are needed to test the immune suppression function of MDSCs in T1D. 
 
 
 
Introduction 
 
Autoimmune Diabetes (AID) also known as 
type 1 diabetes (T1D) usually develops as a result 
of the triad of environmental factors, genes and 
immune system interaction [1]. Several genes like 
cytotoxic T-lymphocyte antigen 4 (CLTA4), major 
histocompatibility complex class II (MHC II), and 
others drive an immune response that controls the 
T1D outcome. The over-reactive immune system 
also occurs in AID patients [2]. Subsequently, loss of 
insulin-producing pancreatic β – cells, caused by 
infiltrating immune cells, results in hypoinsulinemia, 
hyperglycemia and fatal complications. To date, no 
means for preventing or curing AID exists [3]. 
Numerous strategies have been developed, trying to 
restore physiological insulin production in diabetic 
patients [4]. Despite some progress, restoring self - 
tolerance or specifically correcting autoimmunity 
remains a crucial step toward reversing AID. In 
this respect, research and clinical interest in 
regulatory Treg and MDSC have increasingly grown 
[5][6][7]. 
Myeloid-derived suppressor cells (MDSCs) 
are a heterogeneous population of cells that are 
defined by their myeloid origin, immature state and 
ability to suppress T cell responses potently. Under 
normal conditions, they differentiate into dendritic 
cells, macrophages and granulocytes. However, in 
pathological states such as infection, inflammation 
or cancer, there is an arrest of differentiation of this 
population of cells resulting in their accumulation 
[8][9][10]. The composition and percentage of 
MDSCs were found to vary according to disease 
nature. However, MDSC of different origins has 
potent suppressive activities [11][12]. 
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Human MDSCs were initially defined as 
HLA-DR
-
CD33
+ 
or CD14
-
CD11b
+ 
cells, with both 
phenotypes identifying cell populations with T cell 
suppressive activity [13][14]. Recently, other markers 
have defined MDSC subsets, including CD14- 
positive monocytic MDSC (Mo-MDSC) and CD15- 
positive granulocytic MDSC (G-MDSC). The 
expression of CD14 on MDSCs as a Mo-MDSC 
marker was initially controversial but has now 
become accepted. The CD14 expression is difficult 
to be used as a lineage marker as low levels of this 
marker are expressed on polymorphonuclear 
leukocytes (PMNs). Therefore, differentiation between 
CD14
bright
 versus CD14
low 
in the assessment of 
MDSCs is crucial [15]. 
Accumulative evidence shows that T- cells 
play a pivotal role in AID pathogenesis through the 
secretion of inflammatory cytokines and destruction of 
β-cells [16]. Accordingly, the importance of studying 
MDSCs emerges since several therapeutic strategies 
targeting MDSCs could inhibit immune responses in 
the setting of autoimmune disease [17]. 
This study aimed to determine the frequency 
of MDSCs and study MDSCs subsets in type1 
autoimmune diabetes and to evaluate the effect of 
diabetic nephropathy on the frequency of MDSCs 
for later studying of their suppressor activities on T 
cells and their potential therapeutic use in AID. 
 
 
Material and Methods 
 
Subjects 
This study enrolled thirty type 1 diabetic 
patients from the diabetes outpatient clinic of National 
Research Center (NRC) and thirty age - and gender-
matched healthy controls. In particular, inclusion 
criteria for patients were age range 20 - 60 years. The 
first group of patients included 12 T1D without 
diabetic nephropathy. Diagnosis of diabetes was 
based on criteria of the American Diabetes 
Association [18] 
The second group of patients included 18 T1D 
with diabetic nephropathy. Diagnosis of diabetic 
nephropathy is based on detection of abnormal levels 
of urinary albumin in diabetic patients combined with 
exclusion of other causes of albuminuria. Albumin 
measurements are defined as follows [19]: 
 1. Normal albuminuria: urinary albumin 
excretion < 30 mg/24h; 
 2. Microalbuminuria: urinary albumin 
excretion in the range of 30 - 299 mg/24h; 
 3. Macroalbuminuria: urinary albumin 
excretion ≥ 300 mg/24h. 
Exclusion criteria included Type 2 diabetes, 
any febrile illness during the last three months, 
chronic inflammatory/rheumatic disease or other 
chronic kidney disease. 
Clinical data were collected from patients’ 
records. Informed consent was obtained from each 
subject. Approval for the study was obtained from 
the Ethics Committee of National Research Center, 
Cairo, Egypt (Number of the approval: 15160). 
 
Samples 
From each subject, 3 ml venous blood was 
taken and divided into three sterile tubes. Two tubes 
were sent to the Clinical Chemistry laboratory in 
NRC for the determination of fasting blood sugar 
level; two hours postprandial blood sugar test, 
glycated haemoglobin level. The third tube was sent 
to the flow cytometry unit in Kasr El Aini hospital for 
immunofluorescent staining for the determination of 
myeloid-derived suppressor cells. 
Samples were kept at room temperature 
and were not shaken. They were analysed within 
24 hours of venipuncture. 
Microalbuminuria was defined by urinary 
albumin excretion of at least 30 mg in a 24 - hour 
period 
 
Flowcytometry 
First, isolation of human PBMCs was 
performed using a Ficoll - Hypaque density gradient 
before antibody staining. Second, 100 µl of test 
sample was incubated with 20 µl of specific 
monoclonal antibodies: CD33 PE (Beckman Coulter, 
USA), CD14 - FITC (Beckman Coulter, USA) and HLA 
- DR PC5 (Beckman Coulter, USA) at room 
temperature in the dark, same species isotypes served 
as a negative control. 
After 20 min of incubation, 2 ml of Phosphate 
Buffer Saline were added to each tube of monoclonal 
treated cells. The mixtures were then centrifuged for 5 
min at 150 xg at room temperature followed by 
discarding the supernatant and resuspending the 
pellet in 3 ml PBS. Cell analysis was performed using 
CYTOMICS FC 500 Flow Cytometer (Beckman 
Coulter, FL, USA) and analysed using CXP Software 
version 2.2. 
 
Statistical analysis 
The data were analysed using Microsoft 
Excel 2010 and statistical package for social science 
(SPSS version 24.0) for Windows (SPSSIBM, 
Chicago, IL). Results were expressed as mean ± SD 
with 95% confidence interval using the range for 
quantitative variables, and using the frequencies and 
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percentage for qualitative ones; a p- value < 0.05 
was considered statistically significant. Spearman's 
rank correlation coefficient (r) was done to show the 
correlation between different parameters in this study. 
Diagnostic parameters of subjects were compared 
using the non-parametric Wilcoxon – Mann - Whitney 
U - test, whereas the parametric parameters were 
compared using the Paired samples (t) test. Also, Chi-
square (
2
) test was used for comparison of 
categorical data. Whenever the expected values in 
one or more of the cells in a 2 x 2 tables were less 
than 5, Fisher exact test was used instead and 
using linear by linear association in larger than 2 x 2 
cross - tables. 
 
 
Results 
 
Characteristics and clinical data 
A total number of 30 T1D patients were 
included in the study. Diabetic patients with 
nephropathy represented 60% (n = 18) and diabetic 
patients without nephropathy represented 40% (n = 
12). A control group of healthy individuals (n = 30) 
were also included. Demographic and laboratory 
data of Patients and controls are shown in Table 1. 
Human MDSCs are immature myeloid cells that 
express the cell surface antigen CD33 and weakly 
express HLA-DR being a mature myeloid cell marker 
[20]. Accordingly, we used the surface markers CD33
+
 
within HLA-DR neg cells to identify MDSCs and 
compared the frequency of MDSCs in the peripheral 
blood of the two groups of patients - diabetes with 
nephropathy (Figure 1a) and diabetes without 
nephropathy (Figure 1b) - and of the control group as 
well (Figure 1c). 
To determine the percentage of MDSCs in 
patients, acquired cells were first gated based on the 
expression of HLA DR (PC5). The PC5 subset was 
comprised of HLA DR
- 
cells. Within this population, 
the fraction of cells expressing CD33 (PE) and CD14 
(FITC) was determined. 
Table 1: Demographic and laboratory data of the two groups of 
patients and control 
 
Descriptive parameters 
Control N=30 Diabetic patients 
Without 
nephropathy 
N=12 
Diabetic patients 
With nephropathy 
N=18 
 
Age 
Range 28 - 55 35 - 55 28 – 56 
Mean ± SD 38.3 ±  5.3 49.1 ± 5.3 40.0 ± 8.7 
 
Sex 
Female 21 (70.0%) 9 (75.0%) 15(83.3%) 
Male 9 (30.0%) 3 (25.0%) 3(16.7%) 
 
FBS mg/dl 
Range 80-120 86-243 98-272 
Mean ± SD 95.6 ± 13.8 (125.4 ± 47.7) (123.3 ± 40.3) 
 
PP.BS mg/dl 
Range 90-150 110-242 120-250 
Mean ± SD 119.6 ± 20.6 (152.9 ± 32.3) (155.1 ± 27.9) 
 
Hba1C % 
Range 3-5.5 4.5-7.0 5.1-7.2 
Mean ± SD 4.22 ± 0.79 (5.7 ± 0.7) (5.8 ± 0.6) 
Microalbumin 
mg/24h 
Range  
--------- 
16.5-29.0 185-310 
Mean ± SD (23.97 ± 2.9) (253.8 ± 33.8) 
FBS: Fasting blood sugar, PP; BS = postprandial blood sugar; SD = standard deviation. 
a)  
b)  
c)  
Figure 1: a) Flowcytometry analysis of the percentage of CD33+ HLA-DR- 
MDSCS in T1D patients with diabetic nephropathy; b) Flowcytometry analysis 
of the percentage of CD33+ HLA-DR- MDSCS in T1D patients without 
diabetic nephropathy; c) Flowcytometry analysis of the percentage of CD33+ 
HLA-DR- MDSCS in healthy control group 
 
Increased frequency of CD33
+ 
HLA - DR
-
MDSCs in the peripheral blood of T1D 
patients 
The frequency of total MDSCs was increased 
in the peripheral blood of type 1 diabetes patients 
compared to the control group with a highly 
significant difference (Figure 2), (Table 2). 
 
Figure 2: Mean of MDSCs in the study groups 
 
Then, we subdivided the group of diabetic 
patients according to nephropathy into two groups: 
Diabetic patients without nephropathy (n = 12), and 
Diabetic patients with nephropathy (n = 18), and 
we compared the frequency of total MDSCs among 
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the two groups and the control group. We found that 
the frequency of total MDSCs in a diabetic patient 
with nephropathy was increased than diabetic 
patients without nephropathy with a highly significant 
difference (P - value < 0.001) (Figure 2), (Table 2). 
Table 2: The frequency of MDSCs in both groups of T1D and 
the control group. Percentage of the two subpopulations of 
MDSCs CD14
+
 and CD14
-
 in both patients group compared to 
the control group 
 
 
Descriptive parameters 
 
Control  
N = 30 
Diabetic 
patients 
 
Without 
nephropathy 
N = 12 
Diabetic 
patients 
 
With 
nephropathy 
N = 18 
Total 
 
Diabetic 
Patients 
MDSCs Range 0.3-1.01 2.4-3.8 3.0-10.3 2.4-10.3 
Mean ± SD 0.72 ± 0.24 (3.13 ± 0.5) (5.14 ± 2.3) (4.4 ± 2.07) 
CD14 
Positive 
Range 98.9-99.7 96.0-97.5 87.5-99.5 87.5-99.5 
Mean ± SD 99.3 ± 0.3 (96.9 ± 0.6) (95.4 ± 3.8) (96.5 ± 3.02) 
CD14 
Negative 
Range 0.1-1.1 2.5-4.0 0.52-12.5 0.52-12.5 
Mean ± SD 0.62 ± 0.33 (3.09 ± 0.56) (4.6 ± 3.8) (3.98 ± 3.0) 
 
The total population of CD33
+
 HLA–DR
-
 
MDSCs obtained from peripheral blood of T1D 
patients were further divided into two 
subpopulations of cells expressing CD14
+
 and CD14
-
. We compared the two subsets in the two groups of 
diabetic patients in relation to the control group. 
Then, we compared the percentage of these 2 
MDSCs subsets in the two groups of diabetic patients 
(Table 2). 
Analysis of the previous results of MDSC 
subsets (CD14
+
 and CD14
-
) demonstrated that all 
healthy individuals in the control group, diabetic 
patients with nephropathy and diabetic patients 
without nephropathy had higher numbers of CD14
+
 
MDSC and lower number of CD14
-
 MDSCs. 
The percentage of CD14
+
 subset tended to 
decrease in the T1D patients compared to the 
control group even though their absolute number 
increased due to the increase of total MDSCs. On the 
contrary, Percentage of CD14
-
 subset has increased in 
T1D patients than the control group. 
Among the diabetes patients, the percentage 
of CD14
+
 subset was less in diabetic patients with 
nephropathy than diabetic without nephropathy. On 
the contrary, the percentage of CD14
-
 was increased 
in diabetic patients with nephropathy than diabetic 
without nephropathy (Figure 3), (Table 2). 
 
Figure 3: Comparison of CD14
+
 and CD14
-
 subsets among the three tested 
groups 
In Brief, comparing diabetic patients with 
and without nephropathy to the control group 
demonstrated a highly significant difference in the 
frequency of total MDSCs and a significant 
difference in the proportion of CD14
+
 and CD14
-
 
subset of MDSCs among the three groups. 
 
Correlation between CD33
+
 HLA - DR
-
 
MDSCs and HbA1C 
We examined the possible correlations 
between CD33
+
 HLA - DR
-
 MDSCs and HbA1C in T1D 
patients. As shown in Figure 4, CD33
+
 HLA - DR
-
 
MDSCs were positively correlated with levels of 
HbA1C (r = 0.702, P < 0.001) (Figure 4). 
 
Figure 4: Positive correlation (direct proportion) between MDSCs and Hba1c 
(r = 0.702; P < 0.001) 
 
Correlation of CD33+ HLA - DR
-
 MDSCs, 
microalbumin 
We examined the possible correlations of 
CD33
+
 HLA - DR
-
 MDSCs, levels of microalbumin in 
T1D patients. As shown in Figure 5, CD33
+
 HLA-DR
-
 
MDSCs were positively correlated with levels of 
microalbumin (r = 0.814, P < 0.001) (Figure 5). 
 
Figure 5: Positive correlation (direct proportion) between MDSCs and 
microalbumin (r = 0.814; P < 0.001) 
 
 
 
Discussion 
 
MDSCs are a heterogeneous population of 
cells that may inhibit the immune response, which 
makes them important goals for the treatment of 
autoimmune diseases [21]. Some studies focused 
on the importance of MDSCs, and they suggested 
the possibility of their use in the prevention and 
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treatment of T1D due to their potential suppressor 
function [22]. On the contrary, MDSCs was found at 
different stages of differentiation, accumulating in 
various pathological conditions like inflammation and 
autoimmune diseases [21]. These findings appear to 
be ambiguous. In our work, we studied the frequency 
of MDSCs in T1D patients. 
According to Kracht et al. destruction of 
Beta-islets of the pancreas and development of 
autoimmune T1D and the antitumour immunity may 
share some common pathways and may differ in 
others [23]. Environmental factors have an important 
role in the aetiology of T1D as well as the antitumor 
immune response. The subsequent inflammation 
induces massive destruction of the target cells. Both 
beta cells and tumour cells respond to inflammatory 
signals by releasing proinflammatory cytokines such 
as (IL-1b), chemokines (CCL2, CXCL10) [24][25], 
and by producing neoantigens that are recognised by 
a tumour - specific or autoreactive T cells [26][27]. 
Overexpression of human leukocyte antigen (HLA) is 
an early indicator of islet distress, seemingly before 
insulitis in the case of T1D [28]. While tumours can 
evade immune detection by downregulation of HLA 
class I or direct inhibition of lymphocytes [29]. The 
hyperexpression of HLA class I by beta – cells 
together with the production of chemo-attractants, 
results in amplification of the immune response [30]. 
This, in conjunction with signals produced by 
infiltrating immune cells (CD8 and CD4 T cells), that 
lead to a microenvironment comparable to antitumor 
response. The microenvironment of progressive 
tumours contains numerous cells that promote 
tumour growth. Among these cells, we can find 
MDSCs that prevent cytotoxic T cell activity [31]. In 
case of T1D, Whitfield - Larry et al., reported an 
increased frequency of MDSCs in T1D patients in 
contrast to the islet of diabetic Non- Obese Diabetic 
(NOD) mice that showed fewer MDSCs suggesting 
an underlying defect in immune suppression [22]. 
Even though studies of MDSCs in autoimmunity in mice 
are frequent, only a few data about MDSCs in human 
autoimmune diseases are available. 
Our work reveals a highly significant increase 
in the frequency of CD33
+
 HLA-DR
-
 MDSCs in the 
peripheral blood of T1D patients. The underlying 
mechanism of this increase, however, is not well 
known. In a previous study, Haile et al. had 
described an increased frequency of peripheral 
MDSCs in Crohn's disease and ulcerative colitis 
[32]. A strong association reported in their study was 
that most of their patients followed an 
immunosuppression regimen. In our study, none of 
the T1D patients was on immunosuppressive 
treatment, yet our results similarly show an 
increased frequency of peripheral MDSCs. Therefore, 
we suggest that the high frequency of peripheral 
MDSCs might be a general finding in autoimmune 
diseases and not a result of the use of 
immunosuppressive drugs. 
A possible explanation of MDSCs increase 
in T1D raised when a previous cancer study 
suggested that some factors produced by cancer 
cells and inflammatory cells may have a role in the 
increased frequency of MDSCs [33][34]. These 
factors included three cytokines known to be 
important in the pathogenesis of T1D which are IFN 
- gamma, IL-1beta, and IL-6 [35][36]. So, increased 
frequency of peripheral MDSCs in T1D patients is 
likely a result of the elevation of these cytokines. 
Some recent studies reported a relation 
between end-stage renal disease (ESRD) and 
expansion of MDSCs [37], so we investigated the 
effect of renal complication of T1D known as 
diabetic nephropathy on the frequency of MDSCs 
and whether MDSCs would significantly differ in T1D 
without nephropathy than in T1D with diabetic 
nephropathy. We found a highly significant increase 
of MDSCS in diabetic patients with nephropathy 
than in those without nephropathy. 
Human MDSCs can be identified as CD33
+
 
HLA-DR
−
, and further divided into 2 subsets: 
granulocytic CD14
−
 and monocytic CD14
+
 MDSCs 
[38][39]. In our study, we analysed the peripheral 
blood of T1D patients with and without diabetic 
nephropathy for the presence of 2 recently 
described MDSCs subpopulations (G-MDSCs and M-
MDSCs). Our data demonstrate that MDSCs show 
highly significant increase in the peripheral blood of 
patients with T1D compared to healthy controls. M-
MDSC phenotype (CD14
+
 CD33
+
 HLA–DR
-
) were 
the most abundant MDSCs subpopulation in the 
blood of healthy control group, T1D with and without 
nephropathy. To our knowledge, this is the first study 
that compares the difference in the percentage of 
MDSCs subsets (CD14
+
 and CD14
-
) in T1D and 
stating the decrease in the percentage of CD14
+
 
and the increase in CD14
-
 in T1D compared to the 
control group. 
In conclusion, this study reports an increase in 
MDSCs in the peripheral blood of T1D patients versus 
healthy control with a predominance of the CD14
+
 
MDSCs subset. Considering the immunosuppressive 
effect of MDSCs, we realise that continuous 
monitoring of the composition of these cells in T1D 
patients may be highly rewarding. Further future 
studies are needed to test the immune suppression 
function of MDSCs in T1D and their potential use 
as targets to inhibit the immune response in 
autoimmune disease. 
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